News & Updates
Filter by Specialty:
POSEIDON: Dual ICIs plus chemo up survival in first-line mNSCLC
20 Jan 2023
byKanas Chan
Adding two immune checkpoint inhibitors, tremelimumab (T) and durvalumab (D), to platinum-based chemotherapy (CT) significantly improves overall survival (OS) and progression-free survival (PFS) vs CT alone in first-line treatment of metastatic non-small-cell lung cancer (mNSCLC), without causing a meaningful increase in toxicity, according to results of the phase III POSEIDON trial.
POSEIDON: Dual ICIs plus chemo up survival in first-line mNSCLC
20 Jan 2023
Total diet replacement shows promise for difficult-to-treat asthma
19 Jan 2023
A low-calorie total diet replacement program (Counterweight-Plus) is safe and improves asthma control and quality of life in patients with difficult-to-treat asthma and obesity, according to 16-week data from a recent study.
Total diet replacement shows promise for difficult-to-treat asthma
19 Jan 2023
MRI- vs CT- guided radiotherapy for localized prostate cancer linked to lower toxicity, symptom burden
19 Jan 2023
byJairia Dela Cruz
Magnetic resonance imaging (MRI) guidance in stereotactic body radiotherapy (SBRT) for prostate cancer offers significant advantage over computed tomography (CT) guidance, with lower physician-scored toxic effects and patient-reported symptom burden, according to the results of the phase III MIRAGE* study.
MRI- vs CT- guided radiotherapy for localized prostate cancer linked to lower toxicity, symptom burden
19 Jan 2023
Pain, discomfort persist in JIA patients despite medication use
18 Jan 2023
Problems with pain or discomfort continue to bother young adults with juvenile idiopathic arthritis (JIA) despite their constant use of medication, a study has shown.
